Celera’s Database Revenues Continue to Slide
Quarterly revenues for Celera Genomics continue to drop as the company phases out its informatics business.
Last week, the company reported revenues of $8.2 million for the quarter ended Dec. 31, 2004, a nearly 60-percent drop from $19.2 million in revenues that the company reported in the comparable period of 2003.
In a statement, Celera attributed the decline to the “continuing expiration of Online/Information Business customer agreements and the discontinuation of most of the business operations of Paracel during the first fiscal quarter of 2005.”
The company said it expects revenues to continue their downward slide, to a range of $25 million to $30 million for its 2005 fiscal year, which ends June 30, 2005.
The company posted revenue of $60.1 million for its 2004 fiscal year.
GSK Licenses Jubilant’s PathArt
Jubilant Biosys last week said that GlaxoSmithKline has licensed its PathArt database of manually curated pathways.
The announcement follows on two PathArt licensing agreements that Jubilant disclosed two weeks ago, with Bayer Healthcare and the Research Center for Genomic Medicine at Japan’s Saitama Medical School.
BioWisdom Partners with Spotfire
Biomedical ontology developer BioWisdom said last week that it has signed a co-development and co-marketing agreement with Spotfire.
Under the agreement, the companies will merge BioWisdom’s Sofia platform and Spotfire’s DecisionSite “into a jointly marketed combined solution.”
BioWisdom’s Sofia platform gathers scientific and commercial intelligence from different structured and unstructured data sources to generate ontologies that can be deployed in a wide range of healthcare applications, according to the company.
Following the integration with DecisionSite, researchers will be able to visualize information in the ontologies from multiple perspectives.
RNAi Co. Licenses GeneGo’s MetaCore
GeneGo said last week that it has licensed its MetaCore pathway database to Japan’s RNAi Co., a biotechnology company developing therapeutics using RNA interference.
“We looked at several systems biology packages and found that MetaCore suited our needs the best,” said Yukikazu Natori, chairman of RNAi, in a statement. “We needed a flexible partner that was willing to integrate with our current siRNA technology.”
RNAi Co. is GeneGo’s first customer in Japan, the company said.
OmniViz Expands Software Collaboration with J&J
OmniViz said last week that it has renewed and expanded a multi-year collaboration with Johnson & Johnson Pharmaceutical Research & Development.
The companies first began collaborating in 2000.
Under the expanded agreement, J&J and OmniViz will co-develop a new version of the OmniViz data visualization software, including pathway analysis and drawing features to facilitate decision making in drug discovery and other pharmaceutical applications.
The new software is expected to take advantage of experimental data, scientific literature, pathways, and business and market information.
Agencourt to Use Matlab for DNA Analysis
Agencourt Bioscience is using The MathWorks’ Matlab modeling language and Image Processing Toolbox to collect and analyze large volumes of DNA data, The MathWorks said last week.
Agencourt engineers are using the software tools to develop applications and to scale their algorithms to extract large amounts of DNA sequence at an industrial level, the company said.
Financial terms of the agreement were not provided.
IBM Helps University of Arizona Build Life Science Data-Storage System
The Arizona Research Laboratories at the University of Arizona will build a data-storage infrastructure with a technology grant from IBM, ARL said last week.
Under the IBM Shared University Research grant, researchers from IBM and the University of Arizona will build an environment to store large amounts of diverse types of data, including MRI images, genomic sequences, and microscopy images. The system will use IBM’s TotalStorage disk and tape systems. The project will involve 500 UA researchers from five areas of life science research.
IBM plans to measure how the data are moved and accessed over time, helping it to design future software and hardware.